Yunkang Group Limited Stock

Equities

2325

KYG9889T1067

Healthcare Facilities & Services

Market Closed - Hong Kong S.E. 04:08:22 2024-04-29 am EDT 5-day change 1st Jan Change
11.12 HKD 0.00% Intraday chart for Yunkang Group Limited +0.72% -9.59%

Financials

Sales 2023 892M 123M 964M Sales 2024 * 979M 135M 1.06B Capitalization 6.19B 854M 6.69B
Net income 2023 -102M -14.09M -110M Net income 2024 * -25M -3.45M -27.02M EV / Sales 2023 7.6 x
Net cash position 2023 * - 0 0 Net cash position 2024 * 547 75.54 591.24 EV / Sales 2024 * 6.32 x
P/E ratio 2023
-65.8 x
P/E ratio 2024 *
-257 x
Employees 1,510
Yield 2023 *
40.9%
Yield 2024 *
32.5%
Free-Float 25.97%
More Fundamentals * Assessed data
Dynamic Chart
1 week+0.72%
Current month-0.36%
1 month-0.36%
3 months-2.11%
6 months-7.33%
Current year-9.59%
More quotes
1 week
10.96
Extreme 10.96
11.12
1 month
10.04
Extreme 10.04
11.18
Current year
10.04
Extreme 10.04
12.30
1 year
10.04
Extreme 10.04
14.88
3 years
6.60
Extreme 6.6
19.18
5 years
6.60
Extreme 6.6
19.18
10 years
6.60
Extreme 6.6
19.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 18-07-19
Director of Finance/CFO 45 21-02-06
Corporate Officer/Principal 58 -
Members of the board TitleAgeSince
Director/Board Member 67 -
Director/Board Member 52 -
Director/Board Member 64 23-08-29
More insiders
Date Price Change Volume
24-04-29 11.12 0.00% 194 780
24-04-26 11.12 +0.36% 61,500
24-04-25 11.08 +0.18% 60,500
24-04-24 11.06 0.00% 64,500
24-04-23 11.06 +0.18% 58,500

Delayed Quote Hong Kong S.E., April 29, 2024 at 04:08 am EDT

More quotes
Yunkang Group Ltd is a China-based Company mainly engaged in the provision of diagnosis testing services. The Company operates three segments. Diagnosis Testing segment provides diagnosis testing to hospital and non-medical clients, mainly including routine diagnostic testing, routine pathological examination, infectious disease diagnostic testing, genetic disease diagnostic testing and early cancer detection. Hospital Management Business segment provides management services for the community clinics. Research & Development Institution segment is engaged in the research and development of testing kits. The Company primarily provides services for hospitals and other medical institutions, and commercial entities such as financial institutions and insurance companies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
10.29 CNY
Average target price
12.93 CNY
Spread / Average Target
+25.60%
Consensus

Annual profits - Rate of surprise